Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 10, 2006

Alligator Bioscience and AlgoNomics Ink Therapeutic Protein Partnership

  • Alligator Bioscience and AlgoNomics entered into a collaboration in which the latter will employ its Epibase® platform to complement the former in the optimization of therapeutic proteins both in their internal projects and in collaborative projects with customers.

    “All proteins delivered as biopharmaceuticals could render an immune response. For Alligator it is of great importance to make a responsible risk assessment on any new project. We are therefore grateful to be able to work with AlgoNomics, delivering a state-of-the-art technology, for investigating the theoretical consequence of an immune response,” states Gun-Britt Fransson, CEO of Alligator Bioscience.

    The collaboration allows Alligator to maximally reduce immunogenicity upon optimization of protein therapeutics with its ssDNA recombination technology FIND®.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »